Model portefeuille
Rendement portefeulle
+12.035 %

Rendement AEX
+33.325 %

Startdatum
01-01-2009

Startwaarde portefeuille € 74082.37

Startwaarde AEX
€ 245.94


Laatste update:
29-01-2010


Beleggingsadviezen
 Crucell and Scripps Research discover and describe ... 10-08-2012
 JUDGMENT ISSUED IN CRUCELL N.V. BUY-OUT PROCEEDINGS 28-02-2012
 Crucell Discovers Important New Antibody Against In... 08-07-2011
 Johnson & Johnson Acquires 98.89% of Issued Crucell... 09-03-2011
 Johnson & Johnson Completes Tender Offer for Crucel... 22-02-2011
 Crucell Reports Fourth Quarter and Full Year 2010 R... 07-02-2011
 Johnson & Johnson Launches Recommended Public Offer... 08-12-2010
 Johnson & Johnson and Crucell Progress Update: Expe... 01-12-2010
 Crucell Reports Third Quarter 2010 Results 09-11-2010
 Johnson & Johnson and Crucell Provide Progress Upda... 30-10-2010
 Crucell Puts Temporary Hold on Shipments of Quinvax... 28-10-2010
 Crucell to Convene Initial Informational Extraordin... 14-10-2010
 Johnson & Johnson and Crucell Reach Agreement on In... 06-10-2010
 Brief over Crucell 27-09-2010
 NIEUWE GENERATIE BEDRIJVEN WEET KANSEN TE GRIJPEN 25-09-2010
 DSM and Crucell announce expansion of PERCIVIA PER.... 23-09-2010
 Aeras and Crucell Announce Phase II Clinical Trial ... 22-09-2010
 Johnson & Johnson and Crucell in advanced negotiati... 17-09-2010
 Crucell Reports Record Revenues in Second Quarter 2... 17-08-2010
 Crucell and Harvard (BIDMC) Join Forces with IAVI t... 11-08-2010
 Crucell Reaches Agreement with Sanofi Pasteur on Pr... 08-07-2010
 Crucell Announces Start of Universal RSV Vaccine Pr... 24-06-2010
 Crucell 2010 Annual General Meeting of Shareholders... 04-06-2010
 Crucell and NIH Announce Start of Malaria Vaccine T... 11-05-2010
 Crucell Announces First Quarter 2010 Results 11-05-2010
 Crucell Announces New Award of $110 Million for Pae... 06-05-2010
 Aeras and Crucell Announce Start of Phase II TB stu... 14-04-2010
 Crucell Announces Collaboration with GlaxoSmithKlin... 06-04-2010
 Crucell's Supervisory Board Nominates Mr. W. Burns,... 15-03-2010
 Crucell Announces Record Revenues and Profits for F... 09-02-2010
 Crucell launches global brand to reflect and reinfo... 16-11-2009
 Crucell Announces Third Quarter 2009 Results 03-11-2009
 Crucell HIV Vaccine: Promising Preliminary Results ... 21-10-2009
 Crucell Rabies Monoclonal Antibody Combination: Pos... 20-10-2009
 Crucell Strengthens its Vaccine Sales in the UK wit... 30-09-2009
 Johnson & Johnson and Crucell Announce Strategic Co... 28-09-2009
 Crucell Receives NIH Award for the Development of I... 18-08-2009
 Crucell, New awards of $300 million for Quinvaxem┬«... 17-08-2009
 Crucell Announces Second Quarter 2009 Results 11-08-2009
 MVI and Crucell Announce Collaboration new Malaria ... 29-07-2009
 Crucell Announces Positive Results of Phase II Rabi... 24-06-2009
 Crucell 2009 Annual General Meeting of Shareholders... 05-06-2009
 Crucell Announces First Quarter 2009 Results 06-05-2009
 Aeras and Crucell Announce Start of TB Infant Study... 28-04-2009
 Crucell's Revolutionary Antibody for Universal Ther... 27-02-2009
 DSM and Crucell Sign Agreement with Bioceros to Ser... 10-02-2009
 Crucell Announces Profits for Full Year 2008 05-02-2009
 DSM and Crucell Announce PER.C6┬« Research License ... 18-12-2008
 Crucell Signs Second Exclusive License Agreement wi... 17-12-2008
 Crucell Announces Excellent Results for Influenza A... 11-12-2008


Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL